Synagis Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The synagis market research report is one of a series of new reports that provides synagis market statistics, including the synagis industry global market size, regional shares, competitors with the synagis market share, detailed synagis market segments, market trends, and opportunities, and any further data you may need to thrive in the synagis industry. This synagis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising R&D expenditures, a rise in the prevalence of RSV, growing demand for personalized and telemedicine, a growing aging population, increasing pediatric population in emerging markets. Major trends in the forecast period include the development of RSV treatment, biosimilar development, clinical trial outcomes, advances in treatment and regulatory approvals, and the introduction of combination vaccines.

The rising prevalence of chronic respiratory conditions is expected to drive the growth of the Synagis market in the coming years. Chronic respiratory conditions are long-term illnesses that affect the lungs and airways, causing persistent breathing difficulties. Factors contributing to the increase in these conditions include an aging population, smoking, lifestyle choices, genetic and occupational factors, and environmental pollution. Synagis (palivizumab) is used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and children, reducing the risk of complications and flare-ups in those with existing respiratory conditions. For example, in December 2023, Public Health Scotland reported that the prevalence of doctor-diagnosed asthma rose from 16% in 2021 to 17% in 2022. As the prevalence of chronic respiratory conditions continues to rise, the Synagis market is expected to grow.

The increase in healthcare expenditure is also significantly contributing to the growth of the Synagis market. Healthcare expenditure refers to the financial resources spent on providing medical services, treatments, medications, and preventive care. Several factors, including an aging population, rising chronic disease rates, public health emergencies, and growing demand for healthcare services, are driving the rise in healthcare spending. As healthcare budgets increase, more investment is directed toward preventive treatments for high-risk infants and children. This shift is helping support the growth of the Synagis market by facilitating more funding for medications such as Synagis, which helps prevent serious respiratory illnesses. For instance, in May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure from 2022 to 2023, compared to a 0.9% growth in the previous year. This growing healthcare expenditure is fueling the expansion of the Synagis market.

A notable trend in the Synagis market is the increasing approval of drugs that offer a much-needed preventive treatment for respiratory syncytial virus (RSV). Drug approval is a regulatory process that ensures a new drug is safe, effective, and of high quality based on clinical trial data. In September 2023, AstraZeneca Pharma India Ltd. received approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab as a preventive therapy for RSV. The product is available as an intramuscular injection in 50 mg/0.5 ml and 100 mg/ml presentations in single-dose vials. Palivizumab is indicated for use in infants born at 35 weeks of gestation or less, as well as for children with bronchopulmonary dysplasia (BPD) or significant congenital heart disease (CHD). This approval is a significant milestone for improving RSV care in India, as it is the first preventive therapy for RSV to be made available in the country.

The key company operating in the synagis market is Swedish Orphan Biovitrum AB.

North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in synagis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the synagis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Synagis (palivizumab) is a medication used to prevent severe lower respiratory tract infections caused by the respiratory syncytial virus (RSV) in high-risk infants and children. It is a monoclonal antibody that functions by binding to the RSV virus, preventing it from entering and infecting cells in the respiratory system.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Synagis include RSV prophylaxis, prevention in premature infants with bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), and immunocompromised infants and children. RSV prophylaxis involves preventive measures, such as administering monoclonal antibodies such as Synagis, to reduce the risk of RSV infections, particularly in infants and young children at high risk. It is available in several formulations, such as 50 milligrams (mg)/0.5 milliliters (ml) and 100 milligrams (mg)/1 milliliter (ml), and is distributed through various channels, including wholesale distributors and online retailers. It is used by a wide range of end users, including pediatric and adult patients.

The synagis market consists of sales of pre-filled, single-dose vials and injectable solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.